ArticlePDF Available
Influence of direct to consumer pharmaceutical
advertising and patients’ requests on prescribing
decisions: two site cross sectional survey
Barbara Mintzes, Morris L Barer, Richard L Kravitz, Arminée Kazanjian, Ken Bassett, Joel Lexchin,
Robert G Evans, Richard Pan, Stephen A Marion
Only the United States and New Zealand allow adver-
tising of prescription drugs directed at patients. US
spending on such advertising grew rapidly during the
1990s, reaching $2.47bn (£1650m) in 2000.
1
The
dramatic increase in investment by the US pharmaceu-
tical industry is evidence of an expected effect on sales.
On the rationale that such advertising provides impor-
tant information to consumers and patients who may
benefit from advertised products, pharmaceutical
manufacturers have campaigned in the European
Union
2
and Canada
3
for the relaxing of current regula-
tory restrictions. We examined the relation between
direct to consumer advertising and patients’ requests
for prescriptions and the relation between patients’
requests and prescribing decisions.
Participants, methods, and results
We carried out a cross sectional survey of a cluster
sample of primary care patients in Sacramento,
California, from March to June 2001 and in
Vancouver, British Columbia, from June to August
2000. We used questionnaires to determine the
frequency of patients’ requests for prescriptions and of
prescriptions resulting from requests. Seventy eight
physicians participated in the study, 40 in Vancouver
(all family physicians) and 38 in Sacramento (14
general internists and 24 family physicians).
Patients were all 18 years and over, spoke English,
and provided informed consent. The unit of analysis
was a matched set of patient-physician questionnaires
covering a single consultation. We estimated adjusted
odds ratios using a generalised estimation equation.
We classified drugs as advertised to consumers if they
were among the 50 drugs with the highest US advertis-
ing budgets
4
or were described as advertised to
consumers in Canadian media reports
5
in 1999-2000,
or both.
Sixty one per cent of patients attending physicians’
offices on preset study days participated (1431 total;
683 in Sacramento and 748 in Vancouver). Patients in
the two cities had similar demographic characteristics,
socioeconomic status, and attitudes toward the doctor-
patient relationship. In both settings, income was
higher than average, and 80% were of European
descent.
Patients requested prescriptions in 12% of sur-
veyed visits. Of these requests, 42% were for products
advertised to consumers. The table provides details of
factors associated with requests. Physicians prescribed
the requested drugs to 9% (128) of patients and
requested advertised drugs to 4% (55) of patients. The
prescribing rate was similar for advertised and
non-advertised drugs (about 74%).
After we controlled for health status, demograph-
ics, socioeconomic status, drug payment, and physi-
cians’ sex, specialty, and years of practice we examined
the influence of requests on the probability that a
patient received a new prescription. Patients who
Details from questionnaires given to patients and physicians regarding requests for prescription drugs
Factors associated with
requests
Patients who requested >1 drug (any drug) Patients who requested >1 direct advertised drug
No (%) of patients Odds ratio* (95% CI) No (%) of patients Odds ratio* (95% CI)
Does the patient believe a new prescription was needed?
Yes 75/264 (28.4) 4.2 (2.9 to 6.1) 39/264 (14.8) 5.5 (3.2 to 9.5)
No 100/1167 (8.1) 35/1167 (3.0)
Has the patient requested drugs before?
Yes 67/348 (19.3) 2.0 (1.5 to 2.8) 32/348 (9.2) 2.3 (1.4 to 3.7)
No 108/1083 (10.0) 52/1083 (4.8)
Does the patient have a condition treatable by an advertised drug?
Yes 67/365 (18.4) 1.9 (1.4 to 2.8) 38/365 (10.4) 3.1 (2.0 to 4.9)
No 108/1066 (10.1) 36/1066 (3.4)
Does the patient use advertising as an information source?
Yes 17/84 (20.2) 1.6 (0.9 to 2.8) 13/84 (15.5) 3.2 (1.8 to 6.0)
No 158/1347 (11.7) 61/1347 (4.5)
Does the patient recall having seen adverts for at least three of six listed drugs?
Yes 123/800 (15.4) 1.7 (1.2 to 2.4) 56/800 (7.0) 2.0 (1.1 to 3.6)
No 52/631 (8.2) 18/631 (2.9)
Does the patient recall seeing more than five prescription drugs advertised in the past year?
Yes 111/822 (13.5) 1.3 (0.9 to 1.9) 54/822 (6.6) 2.2 (1.3 to 3.8)
No 64/609 (10.5) 20/609 (3.3)
Total requests 175/1431 (12.2) 74/1431 (5.2)
Requested drug prescribed 128/1431 (8.9) 55/1431 (3.8)
*Odds ratios adjusted for age, sex, health status, income, drug payment, and cluster sampling.
Primary care
Centre for Health
Services and Policy
Research, University
of British Columbia,
Vancouver BC,
Canada V6T 1Z3
Barbara Mintzes
g raduate researcher
Morris L Barer
professor
Arminée Kazanjian
acting director
Ken Bassett
senior medical
consultant
Robert G Evans
professor
Department of
Health Care and
Epidemiology,
University of British
Columbia, Canada
Stephen A Marion
associate professor
Center for Health
Services Research
in Primary Care,
University of
California, Davis,
Sacramento CA,
95817 USA
Richard L Kravitz
professor and director
School of Health
Policy and
Management, York
University, Toronto,
Ontario, Canada
M3J 1P3
Joel Lexchin
associate professor
PC-AWARE, Center
for Health Services
Research in
Primary Care,
University of
California Davis
Medical Centre,
Davis
Richard Pan
executive director
Correspondence to:
B Mintzes
bmintzes@
chspr.ubc.ca
BMJ 2002;324:278–9
278 BMJ VOLUME 324 2 FEBRUARY 2002 bmj.com
requested a prescription (for advertised and non-
advertised drugs) were more likely to receive one
(139/175 v 329/1256, odds ratio 8.7, 95% confidence
interval 5.4 to 14.2).
We asked physicians: “If you were treating another
similar patient with the same condition, would you
prescribe this drug?” An answer of “very likely”
indicated confidence in choice and “possibly” or
“unlikely” indicated some degree of ambivalence. Phy-
sicians were ambivalent about the choice of treatment
in around 40% of cases when patients requested drugs
(advertised and non-advertised, 62/143 v 62/500, 5.4,
3.5 to 8.5) and about half the cases when patients had
requested advertised drugs (30/60 v 62/500, 7.1, 4.0 to
12.6) compared with 12% for drugs not requested by
patients.
Comment
Patients’ requests for medicines are a powerful driver of
prescribing decisions. In most cases physicians
prescribed requested medicines but were often
ambivalent about the choice of treatment. If physicians
prescribe requested drugs despite personal reserva-
tions, sales may increase but appropriateness of
prescribing may suffer. Concerns about the value of
opening up the regulatory environment to permit
direct to consumer advertising in the EU and Canada
seem well justified.
We thank Robert Woollard for assistance with recruitment of
physicians in Vancouver and the physician questionnaire; the
research assistants who administered the survey: Amit Ahuja,
Danielle Lapointe, Michael Tsang, Christine Choi, Vanphen
Chanthalangsy, Min H Ku, Laura Shively, Erica Stranger, Nicol-
let Knopf, Bryan Faulstich, Karry Nagai, and Meridith Cobari;
Sara Lu Vorhes and Valerie Olson for research coordination in
Sacramento; and Nhue L Do and Alicia Mintzes for data entry.
Members of a multidisciplinary expert advisory panel assisted
with the study design: Wendy Armstrong, Alan Cassels,
Jean-Pierre Gregoire, Matthew Hollon, Patricia Kaufert, Joel
Lexchin, Bob Nakagawa, Nancy Ostrove, Richard Pollay, and
Ingrid Sketris.We also thank all of the physicians and patients
who participated in the survey.
Contributors: BM and MLB contributed to all aspects of
study planning, design, analysis, and reporting. RLK, AK, and
KB contributed to interpretation of the data, review of drafts the
manuscript and, to a lesser extent, study planning, questionnaire
design, and data collection. JL and RGE contributed to study
design, interpretation, and review of the manuscript. RP
contributed to US components of study design and organised
and supervised data collection and entry in Sacramento. SAM
contributed to the analysis plan and interpretation and to
subsequent discusssion of these components of the manuscript.
BM and MLB are guarantors.
Funding: Health Transition Fund, Health Canada. Barbara
Mintzes also received a PhD training fellowship for this research
from the National Health Research and Development
Programme (NHRDP) and the Canadian Institutes of Health
Research.
Competing interests: None declared.
Like many journals the BMJ derives income from
pharmaceutical advertising. Direct to consumer advertising of
prescription drugs competes with this channel.
1 IMS Health. US leading products by DTC spend. January 2000-December
2000. Fairfield, CT: IMS Health, 2001. www.imshealth.com/public/
structure/dispcontent/1,2779,1203-1203-143221,00.html (accessed 19
December 2001).
2 Watson R. EC moves towards “direct to consumer” advertising. BMJ
2001;323:184.
3 Therapeutic Products Programme. Direct-to-consumer advertising of
prescription drugs. Discussion document. Ottawa: Health Canada, 1999.
4 Findlay S. Prescription drugs and mass media marketing.Research brief. Wash-
ington, DC: National Institute of Health Care Management, 2000.
www.nihcm.org (accessed 15 March 2001).
5 Silversides A. Direct-to-consumer prescription drug ads getting bolder.
Can Med Assoc J 2001;165:462.
(Accepted 14 January 2002)
Two memorable patients
Two deaths, two lives
Some days in general practice are surprising. On a Tuesday
morning last June I was due to see Miss Jean Smith at 10 20. She
had longstanding angina and recently had worsening
breathlessness. We had discussed my referring her to a specialist,
but in her old fashioned polite and deferential way she’d said, “It’s
up to you, doctor, but maybe we could wait.” I had known her for
many years but had never visited her at home, and I had formed a
picture of her as a spinster, living very much alone, supported by
a few friends from the church.
At 9 50 the telephone rang, and a receptionist told me that
Jean Smith has been found dead in her bedroom by the police.
Could I go and certify the death? I drove down and was greeted
by a policewoman. In the lounge sat an elegantly suited grey
haired man. “Oh hello, Dr Memel, I am so pleased to meet you.
Jean told me so much about you. I came to pick her up for her
appointment with you, like I always do, but the front door was
bolted ....Wearegood friends, of course, but I am not the next of
kin. A two minute chat, then I went upstairs to confirm that she
was dead before returning to my half completed surgery.
An hour later, and Susie came to see me. Her estranged
husband, Donald Hill, had died two weeks earlier from a bleeding
peptic ulcer, alone in his flat. He had been to see me several times
over the previous months, complaining of vomiting and
depression. Slowly from him a story of sad alcoholism had
emerged, of a lonely divorced man whose only solace and social
life was going to the pub.
Susie now told me a very different story. A bubbly lady, she was
my patient 10 years ago, before moving on to one of my partners.
“Don’t you remember how I told you about Donald, how I could
not stand to live with him and his drinking?” I did not remember.
She told me how she had continued to see him regularly over the
years, and still loved him. She was devastated by the way he had
died alone. She showed me a newspaper that she had found in
his flat. On it was scrawled in different places, “Sicked blood, feel
awful,” “Must phone Susie, “Passed out, sick again.
I thought about these two patients recently while attending a
fascinating conference on narrative based medicine, organised by
the BMJ. The anthropologists’ presentations emphasised that
within the stories of people’s lives there are often more than one
account
that of the subject, those of other participants, and that of
the narrator, with each adding his or her own interpretation. These
two patients, who are now dead, told me some things about their
lives but did not tell me others. I asked some questions but did not
ask others, or did not hear the answers, and I fantasised to fill the
gaps. As their general practitioner over many years, I thought that I
knew these two patients well, but I realise that I did not.
David Memel general practitioner, Bristol
(dmemel@airballoon.cix.co.uk)
We welcome articles up to 600 words on topics such as
A memorable patient, A paper that changed my practice, My most
unfortunate mistake, or any other piece conveying instruction,
pathos, or humour. If possible the article should be supplied on a
disk. Permission is needed from the patient or a relative if an
identifiable patient is referred to. We also welcome contributions
for “Endpieces, consisting of quotations of up to 80 words (but
most are considerably shorter) from any source, ancient or
modern, which have appealed to the reader.
Primary care
279BMJ VOLUME 324 2 FEBRUARY 2002 bmj.com
... Direct-to-consumer advertising" (DTC advertising) was first identifyed in relation to pharmaceuticals, and now it is used for a variety of other products. In the '80s the American pharmaceutical industry had proposed to change the marketing approach in order to include consumers (until then the dominant marketing strategy in pharmaceutical industry was geared only to physicians) and this change in approach had lead to Federal Trade Commission (FTC) and FDA regulations of advertising in this sector (Mintzes et al., 2002). As many studies had proven (Gilbody, Wilson & Watt, 2005) DTC advertising can cultivate false faiths among public related to the existence of medication for any disease, leading to medicalisation of all aspects of people's lives (Bonaccorso and Sturchio, 2002). ...
... The topic approached in this paper is a new one in Romania, namely the analysis of so-called "Direct to Consumer Advertising". "Direct-to-consumer advertising" (also called "DTC advertising") referred in the beginning at the marketing of pharmaceuticals (Mintzes et al., 2002), but now it is used also related to other products (Frosch, Krueger, Hornik, Cronholm, Barg, 2007). The existing literature (Huh et al., 2010) had pointed out that the beginning of this type of advertising was around the 1800s. ...
Article
“Direct-to-consumer advertising” (DTC advertising) was first identifyed in relation to pharmaceuticals, and now it is used for a variety of other products. In the ‘80s the American pharmaceutical industry had proposed to change the marketing approach in order to include consumers (until then the dominant marketing strategy in pharmaceutical industry was geared only to physicians) and this change in approach had lead to Federal Trade Commission (FTC) and FDA regulations of advertising in this sector (Mintzes et al., 2002). As many studies had proven (Gilbody, Wilson & Watt, 2005) DTC advertising can cultivate false faiths among public related to the existence ofmedication for any disease, leading to medicalisation of all aspects of people’s lives (Bonaccorso and Sturchio, 2002). This paper aims to test the impact of exposure to advertising for pharmaceutical products on Romanian consumers and to identify the wayin which DTC is functioning in Romania. The methodology of the paper is based on triangulation of two main methods of research: thematic analysis of advertisings at two pharmaceutical products, on the one hand, and semi-directive interviews with twenty patients who had followed those advertisings. The results showed the existence of DTC’s impact on Romanian public. The respondents had declared thatthey could listen to the PG’s recommendations related to pharmaceutical products in “normal” circumstances but in a crisis case (accident, sudden illness) they would go to the pharmacy and ask for the pharmaceutical products they saw in the media. Only in the case of a lack of improvement for their situation they had declared that they would turn to the doctors and medical specialists.
... Malgré cette interdiction en vigueur, bon nombre de Canadiens sont influencés par la PDAC à l'aide des réseaux de télévision provenant des États-Unis où la PDAC est autorisée. La publicité des médicaments d'ordonnance s'adressant aux professionnels de la santé est assujettie à la législation fédérale, de même qu'aux codes de déontologie et de publicité établis par les associations industrielles (Mintzes et al., 2002;Paris et Belloni, 2014). ...
Article
Full-text available
La présente analyse du système de santé du Canada examine les évolutions récentes dans l’organisation et la gouvernance, le financement de la santé, la prestation de soins de santé, les réformes de santé et le rendement du système de santé. L’espérance de vie est élevée, mais a atteint un plateau entre 2016 et 2017 en raison de la crise des opioïdes. Les inégalités socioéconomiques en matière de santé sont importantes, et les écarts marqués et persistants dans les résultats en matière de santé entre les Autochtones et les autres Canadiens représentent un grand défi pour le système de santé, et la société de façon plus générale. Le Canada est une fédération : les provinces et territoires font l’administration de systèmes de couverture de santé pour leurs résidents (appelés « régimes d’assurance-maladie »), alors que le gouvernement fédéral fixe des normes nationales, notamment par la Loi canadienne sur la santé, et est responsable de la couverture de santé de sous-groupes précis. Les soins de la santé sont principalement financés par l’État, avec environ 70 % des dépenses de santé financées par des recettes fiscales générales. Pourtant, les régimes d’assurance-maladie ont des lacunes importantes, comme les médicaments d’ordonnance en dehors de l’hôpital, les soins de longue durée, les soins de santé mentale, et les soins dentaires et de la vue, ce qui explique le rôle important des régimes d’assurance-maladie privés liés à l’emploi et des paiements déboursés par les patients. Le bassin de médecins et d’infirmières est inégal à l’échelle du pays, avec des pénuries chroniques dans les régions rurales et éloignées. Les réformes récentes comprennent une tendance vers le regroupement des régions sanitaires en structures de gouvernance plus centralisées à l’échelle provinciale ou territoriale, et un passage graduel vers l’autonomie des soins de santé par les Autochtones. Il y a également eu une lancée vers l’introduction d’un programme national de couverture des médicaments d’ordonnance (régime d’assurance-médicaments), mais la pandémie de COVID-19 de 2020 pourrait occasionner un virage dans les priorités, vers d’autres problèmes importants du système de santé, comme la mauvaise qualité et la surveillance réglementaire du secteur de soins de longue durée. Le rendement du système de santé s’est amélioré au cours des dernières années, selon les taux de mortalité à l’hôpital, la survie au cancer et les hospitalisations évitables. Des défis majeurs – comme l’accès à des services non couverts par l’assurance-maladie, les délais d’attente pour une consultation avec un spécialiste et les interventions chirurgicales non urgentes, ainsi que la fragmentation et la mauvaise coordination des soins – continueront toutefois de préoccuper les gouvernements dans leur quête d’amélioration du rendement du système de santé.
... Despite the current prohibition, a large proportion of the Canadian public is influenced by DTCA through television from the USA where DTCA is permitted. Advertising of prescription drugs to health professionals is subject to federal legislation as well as advertising and ethical practices codes established by industry associations (Mintzes et al., 2002;Paris & Belloni, 2014). ...
Book
Full-text available
This analysis of the Canadian health system reviews recent developments in organization and governance, health financing, health care provision, health reforms and health system performance. Life expectancy is high, but it plateaued between 2016 and 2017 due to the opioid crisis. Socioeconomic inequalities in health are significant, and the large and persistent gaps in health outcomes between Indigenous peoples and the rest of Canadians represent a major challenge facing the health system, and society more generally. Canada is a federation: the provinces and territories administer health coverage systems for their residents (referred to as “medicare”), while the federal government sets national standards, such as through the Canada Health Act, and is responsible for health coverage for specific subpopulations. Health care is predominantly publicly financed, with approximately 70% of health expenditures financed through the general tax revenues. Yet there are major gaps in medicare, such as prescription drugs outside hospital, long-term care, mental health care, dental and vision care, which explains the significant role of employer-based private health insurance and out-of-pocket payments. The supply of physicians and nurses is uneven across the country with chronic shortages in rural and remote areas. Recent reforms include a move towards consolidating health regions into more centralized governance structures at the provincial/territorial level, and gradually moving towards Indigenous self-governance in health care. There has also been some momentum towards introducing a national programme of prescription drug coverage (Pharmacare), though the COVID-19 pandemic of 2020 may shift priorities towards addressing other major health system challenges such as the poor quality and regulatory oversight of the long-term care sector. Health system performance has improved in recent years as measured by in-hospital mortality rates, cancer survival and avoidable hospitalizations. Yet major challenges such as access to non-medicare services, wait times for specialist and elective surgical care, and fragmented and poorly coordinated care will continue to preoccupy governments in pursuit of improved health system performance.
... There is some empirical evidence about the effects of DTCA on various aspects of behavior, such as number of patient requests for a drug ( Mintzes et al., 2002 ), prescriptions for a drug ( Hansen et al., 2010 ), and compliance taking a drug ( Wozinska, 2005 ). Pharmaceutical advertising has both an informative and persuasive role in drug choice ( Jayawardhana, 2013 ). ...
Article
Consumers receive risk information about prescription drugs from many sources, including from largely unregulated attorney advertisements. This experiment measures subjective risk beliefs about prescription drugs and subjects’ drug-taking behavior in an incentivized setting. Results of the experiment are used to estimate a Bayesian learning model to ascertain the risk levels implied by different information sources and the informational weights subjects place on these sources. Even after people have received scientifically based drug risk information from a doctor and product label, attorney litigation advertising boosts risk beliefs about side effects by an average of 16 out of 100 cases, which is roughly a 50% increase over baseline risk beliefs. Risk beliefs have a significant effect on drug-taking behavior in an incentivized environment. Experience with taking the drug also feeds back into the learning process about risk beliefs. Our experimental results help formalize how consumers update risk beliefs and suggest ways to encourage a learning environment that avoids alarmist updating based on information sources like attorney advertising.
... Despite the current prohibition, a large proportion of the Canadian public is influenced by DTCA through television from the USA where DTCA is permitted. Advertising of prescription drugs to health professionals is subject to federal legislation as well as advertising and ethical practices codes established by industry associations (Mintzes et al., 2002;Paris & Belloni, 2014). ...
Article
Full-text available
This analysis of the Canadian health system reviews recent developments in organization and governance, health financing, health care provision, health reforms and health system performance. Life expectancy is high, but it plateaued between 2016 and 2017 due to the opioid crisis. Socioeconomic inequalities in health are significant, and the large and persistent gaps in health outcomes between Indigenous peoples and the rest of Canadians represent a major challenge facing the health system, and society more generally. Canada is a federation: the provinces and territories administer health coverage systems for their residents (referred to as “medicare”), while the federal government sets national standards, such as through the Canada Health Act, and is responsible for health coverage for specific subpopulations. Health care is predominantly publicly financed, with approximately 70% of health expenditures financed through the general tax revenues. Yet there are major gaps in medicare, such as prescription drugs outside hospital, long-term care, mental health care, dental and vision care, which explains the significant role of employer-based private health insurance and out-of-pocket payments. The supply of physicians and nurses is uneven across the country with chronic shortages in rural and remote areas. Recent reforms include a move towards consolidating health regions into more centralized governance structures at the provincial/territorial level, and gradually moving towards Indigenous self-governance in health care. There has also been some momentum towards introducing a national programme of prescription drug coverage (Pharmacare), though the COVID-19 pandemic of 2020 may shift priorities towards addressing other major health system challenges such as the poor quality and regulatory oversight of the long-term care sector. Health system performance has improved in recent years as measured by in-hospital mortality rates, cancer survival and avoidable hospitalizations. Yet major challenges such as access to non medicare services, wait times for specialist and elective surgical care, and fragmented and poorly coordinated care will continue to preoccupy governments in pursuit of improved health system performance.
... Clinicians also faced competition from the adoption of alternative medicine (Winnick 2005), health social movements (Brown et al. 2004), and online health information (Barker 2008). Clinician surveys report patient pressure to prescribe medications (Bradley and Zito 1997;Kravitz et al. 2005;Mintzes et al. 2002). Physician shopping and requesting second opinions led to greater consumerism (Lupton 1997). ...
Article
Over the past decades, professional medical authority has been transformed due to internal and external pressures, including weakened institutional support and patient-centered care. Today’s patients are more likely to resist treatment recommendations. We examine how patient resistance to treatment recommendations indexes the strength of contemporary professional authority. Using conversation analytic methods, we analyze 39 video recordings of patient-clinician encounters involving pediatric epilepsy patients in which parents resist recommended treatments. We identify three distinct grounds for parental resistance to treatments: preference-, fear-, and experience-based resistance. Clinicians meet these grounds with three corresponding persuasion strategies ranging from pressuring, to coaxing, to accommodating. Rather than giving parents what they want, physicians preserve their professional authority, adjusting responses based on whether the resistance threatens their prerogative to prescribe. While physicians are able to convert most resistance into acceptance, resistance has the potential to change the treatment recommendation and may lead to changed communication styles.
Book
Ghost-Managed Medicine by Sergio Sismondo explores a spectral side of medical knowledge, based in pharmaceutical industry tactics and practices. Hidden from the public view, the many invisible hands of the pharmaceutical industry and its agents channel streams of drug information and knowledge from contract research organizations (that extract data from experimental bodies) to publication planners (who produce ghostwritten medical journal articles) to key opinion leaders (who are sent out to educate physicians about drugs) to patient advocacy organizations (who ventriloquize views on diseases, treatments and regulations), and onward. The goal of this ‘assemblage marketing’ is to establish conditions that make specific diagnoses, prescriptions and purchases as obvious and frequent as possible. While staying in the shadows, companies create powerful markets in which increasing numbers of people become sick and the drugs largely sell themselves. Most agents for drug companies aim to tell the truth, but the truths they tell are drawn from streams of knowledge that have been fed, channeled and maintained by the companies at every possible opportunity. Especially because those companies have concentrated influence and narrow interests, consumers and others should be concerned about how epistemic power is distributed – or ‘political economies of knowledge’ – and not just about truth and falsity of medical knowledge. In pharmaceutical companies’ ideal worlds, medical research, education and marketing would be tightly fused. Doctors trying to educate themselves would turn to companies’ agents, such as researchers and educators sponsored to spread particular messages, local sales reps hired to change doctors’ behaviour, or journalists supplied with news stories. Ghost-Managed Medicine shows that the real world of medicine is not very far from the worlds that the companies want to create. Big Pharma’s many invisible hands are busy throughout medicine, and medicine changes as a result.
Thesis
The quality and expenditure of prescribing have significant implications for patient care and public health and is therefore one of the top priorities within the NHS. However, influencing general practitioners' (GP) prescribing patterns have proved challenging. Resistance to change is influenced by issues such as the GP personal and professional experiences, the relationship with the patient and the perceived tension between primary and secondary care. The aim of this project was to investigate the significant influences on prescribing in two neighbouring Primary Care Trusts (PCT) using multiple methods taking a pragmatic approach. A questionnaire was designed to measure GPs' perceptions of prescribing influence in the two PCTs. From this study, a K-means cluster analysis grouped GPs according to their attitudes towards prescribing influence. Subsequent analysis of prescribing trends revealed that prescribing patterns were related to GPs' perceptions of prescribing influence. Relationships between national and local prescribing initiatives and prescribing trends were analysed and intervention analysis quantified the effects of prescribing change over time. These analyses showed that prescribing incentive schemes have a measurable effect on generic prescribing. Attitudes towards prescribing were further explored in-depth in interviews with GPs and stakeholders from the PCTs and the Health Authority (HA). The analysis exposed different perceptions and areas of potential conflict between stakeholders and GPs in regard to the prescribing agenda. The studies that comprised the thesis were triangulated in discussions on the influencing factors on prescribing. It could be concluded that GPs differed in their perceptions of the factors that influenced prescribing as well as their prescribing practice. The results imply that prescribing interventions need to be developed in line with the views of prescribers and policy makers. Additionally, these interventions should be tailored to different types of GPs holding different perceptions in order to optimise resource use and maximise prescribing change as and where appropriate.
Article
The patient–doctor interaction has changed profoundly in the past decades. In reaction to paternalistic communication patterns, health policy makers have advocated for patient-centered care and shared decision-making. Although these models of medical communication remain still aspirational, patients have become more engaged in advocating for their own health in encounters with physicians. I argue that the engaged patient is a more accurate conceptualization of the changing role of the patient than patient consumerism, the empowered, or expert patient. I examine how the emergence of engaged patients influences the autonomy of health professionals, relates to the rise of the internet as an alternative source of medical information, centers the role of the patient–doctor interaction in public health epidemics, and contributes to health inequities.
Article
Full-text available
Background: Previous attempts to develop an instrument to measure factors that influence prescribing decisions among physicians were relatively insufficient and lacked validation scale. Objective: We present a new tool that attempts to address this shortcoming. Hence, this study aims to develop and validate a self-administrated instrument to explain factors that influence the prescribing decisions of physicians. Methods: The questionnaire was developed based on literature and then subjected to an exhaustive assessment by a board of professionals and a pilot examination before being administered to 705 physicians. Three pre-tests were carried out to evaluate the quality of the survey items. In pre-test 1, after items are generated and the validity of their content is assessed by academics and physicians. In pre-test 2, the scale is carried out with a small sample of 20 respondents of physicians. In pre-test 3, fifty drop-off questionnaires were piloted amongst physicians to test the reliability. Results: On the basis of partial least squares structural equation modelling (PLS-SEM) analyses using SmartPLS 3, the content and convergent validity of the instrument were confirmed with 44 items grouped into four categories, namely, marketing efforts, patient characteristics, pharmacist variables, and contextual factors with 13 reflective constructs. Conclusions: The study outcomes prove that the scale is more valid and reliable for measuring factors that influence the decision of the physician to prescribe the drug. The development and presentation of a scale of thirteen factors related to physicians prescribing decisions help to ensure valid findings and facilitates comparisons of studies and research settings.